ABSTRACT
BACKGROUND Heart-brachium pulse wave velocity (hbPWV) is a measure of proximal aortic stiffness and does not require the technical placement of transducers. To characterize age-associated changes and the clinical utilities of heart-brachium pulse wave velocity (hbPWV), we conducted both cross-sectional and longitudinal analyses and used brachial-ankle pulse wave velocity (baPWV) as a comparative measure.
METHODS Various measures of CVD risk factors and arterial stiffness were obtained in 7,868 adults in the cross-sectional study. In the longitudinal study, 3,710 adults were followed for 9.1 ± 2.0 years. Repeated-measures correlation (rmcorr) and regression analyses were used to characterize associations of PWVs with age and Framingham’s general CVD risk score (FRS).
RESULTS In the cross-sectional study, hbPWV showed a stronger linear (r=0.796) association with age than baPWV (r=0.554). In the longitudinal study, hbPWV also showed a significantly higher rmcorr coefficient with age than baPWV (rrm=0.511 vs. 0.307, P<0.0001). Age-related increases in hbPWV were fairly steady starting from young adults while baPWV displayed accelerated increases with age. A receiver operating characteristic curve analysis indicated that hbPWV depicted a more robust ability to stratify general cardiovascular disease (CVD) risk compared with baPWV (AUC=0.913 vs. 0.833, P<0.0001). The results of the 10-year follow-up study were consistent with the findings of the cross-sectional investigation.
CONCLUSIONS hbPWV exhibits steady and more pronounced increases from an early age and may be more effective in stratifying general CVD risk.
NOVELTY AND RELEVANCE What Is New?
Using the cross-sectional and longitudinal study designs in a large cohort of middle-aged Japanese workers, we confirmed that hbPWV, a promising method for assessing proximal aortic stiffness, undergoes a linear augmentation with age, commencing from an early life stage onward, rendering it a potential marker for discerning CVD risk.
What Is Relevant?
The stiffening of the arterial wall with advancing age is particularly pronounced in the proximal aorta and contributes importantly to elevated risks of CVD, cardiovascular events, and all-cause mortalities.
Clinical/Pathophysiological Implications?
Early-life assessment of proximal aortic stiffening through hbPWV has the potential to mitigate the pervasive impact of CVD on a global scale.
Competing Interest Statement
Hirofumi Tomiyama received funds from Omron Health Care, Asahi Calpis Wellness, and Teijin Pharma. The sponsor (Omron Health Care) assisted in the data formatting (i.e., the brachial-ankle pulse wave velocity data stored in the hard disc of the equipment used to measure the brachial-ankle pulse wave velocity were transferred to an Excel sheet). However, the company played no other role in the design or conduct of the study, that is, in the data collection, management, analysis or interpretation of the data, or the preparation, review, or approval of the manuscript. The remaining authors have no disclosures to make.
Funding Statement
This work was supported by JSPS KAKENHI Grant Numbers 17H02186, 20H04086, 21K18299 (JS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted with the approval of the Ethics Guidelines Committee of Tokyo Medical University (No. SH3450).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author, [HT]. The data are not publicly available due to restrictions (e.g. their containing information that could compromise the privacy of research participants).
